Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 69 (RPL23AP69) is a human processed pseudogene corresponding to ribosomal protein L23a, found on chromosome 7p21.2[2][6]. Pseudogenes, such as RPL23AP69, are genomic sequences similar to known genes but usually non-functional; they arise from gene duplication or retrotransposition events and typically do not encode functional proteins[3][6]. RPL23AP69 has no known protein product, no established biological function, and is not considered a therapeutic target[3][6]. It is frequently listed in genomic and nomenclature databases but is distinguished from the functional ribosomal protein L23a gene (RPL23A), which encodes a component of the 60S ribosomal subunit involved in protein synthesis. There is no reported evidence linking RPL23AP69 to disease phenotypes, pharmacological targeting, or use as a biomarker[3][6]. Its presence is primarily relevant to genomic annotation and nomenclature, not to biomedical research or drug discovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 69 (RPL23AP69).